← Back to Search

PRO Monitoring Strategies for Cancer (BEST-PRO Trial)

N/A
Recruiting
Led By Ravi Parikh, MD
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

BEST-PRO Trial Summary

This trial will evaluate strategies to improve patient reported outcomes and clinician engagement in monitoring them.

Who is the study for?
This trial is for cancer patients starting a new systemic therapy (like chemo or immunotherapy) at certain sites. It's not for those already in another treatment study or who don't want to be part of research that tests how care is delivered.Check my eligibility
What is being tested?
The study compares usual patient-reported outcome (PRO) monitoring with two enhanced methods: one adds reminders and nurse alerts during clinic visits, the other does the same but remotely. The goal is to see if these strategies improve how often patients report health status and nurses engage with this data.See study design
What are the potential side effects?
Since this trial focuses on monitoring methods rather than medications, it doesn't have direct side effects like drugs do. However, participants may experience inconvenience or privacy concerns related to frequent reporting and data sharing.

BEST-PRO Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PRO adherence
Secondary outcome measures
Acute care utilization
Duration of therapy
Percent of patients who trigger an alert for triage nurses (for arms 2 and 3 only)
+4 more

BEST-PRO Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Remote PRO monitoringExperimental Treatment1 Intervention
Remote PRO monitoring plus patient reminders and triage nurse alerts
Group II: Encounter-based PRO monitoringExperimental Treatment1 Intervention
Encounter-based PRO monitoring (usual practice) plus patient reminders and triage nurse alerts
Group III: Usual practiceActive Control1 Intervention
This arm will consist of encounter-based PRO monitoring, in which patients have an opportunity to complete PRO questionnaires via patient portal in advance of clinical encounters or via tablet during clinical encounters. While clinicians will be encouraged to view and discuss PROs with patients during clinical encounters, they will not be prompted to do so in real-time, nor will there be alerts for escalating symptoms.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,672 Previous Clinical Trials
40,926,141 Total Patients Enrolled
Abramson Cancer Center at Penn MedicineLead Sponsor
387 Previous Clinical Trials
145,344 Total Patients Enrolled
Ravi Parikh, MDPrincipal InvestigatorUniversity of Pennsylvania
2 Previous Clinical Trials
4,650 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open vacancies for individuals to take part in this trial?

"The current data hosted on clinicaltrials.gov stipulates that this medical trial is not actively seeking study participants at the moment, as it was last updated on August 24th 2023. Nonetheless, there are 542 other trials presently recruiting patients for various treatments and interventions."

Answered by AI
Recent research and studies
JamaJournal
Overall Survival Results of a Trial Assessing Patient-reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
Basch, Ethan, Allison M. Deal, Amylou C. Dueck, Howard I. Scher, Mark G. Kris, Clifford Hudis, and Deborah Schrag. 2017. “Overall Survival Results of a Trial Assessing Patient-reported Outcomes for Symptom Monitoring During Routine Cancer Treatment”. Jama. American Medical Association (AMA). doi:10.1001/jama.2017.7156.
clinicaltrials.govStudy
Behavioral Economic Strategies to Improve PRO Adherence
2023. "Behavioral Economic Strategies to Improve PRO Adherence". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06013176.
~50 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top